JP2023517754A - 抗ｍｕｃ１－ｓｅａ抗体 - Google Patents

抗ｍｕｃ１－ｓｅａ抗体 Download PDF

Info

Publication number
JP2023517754A
JP2023517754A JP2022555992A JP2022555992A JP2023517754A JP 2023517754 A JP2023517754 A JP 2023517754A JP 2022555992 A JP2022555992 A JP 2022555992A JP 2022555992 A JP2022555992 A JP 2022555992A JP 2023517754 A JP2023517754 A JP 2023517754A
Authority
JP
Japan
Prior art keywords
seq
antibody
muc1
variable region
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022555992A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021186427A5 (enExample
Inventor
ルビンスタイン，ダニエル
レシュナー，ダニエル
Original Assignee
バイオモディファイング・エルエルシー
ラモット アット テル アビブ ユニバーシティ， リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオモディファイング・エルエルシー, ラモット アット テル アビブ ユニバーシティ， リミテッド filed Critical バイオモディファイング・エルエルシー
Publication of JP2023517754A publication Critical patent/JP2023517754A/ja
Publication of JPWO2021186427A5 publication Critical patent/JPWO2021186427A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/852—Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
JP2022555992A 2020-03-18 2021-03-11 抗ｍｕｃ１－ｓｅａ抗体 Pending JP2023517754A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062991077P 2020-03-18 2020-03-18
US62/991,077 2020-03-18
PCT/IL2021/050269 WO2021186427A1 (en) 2020-03-18 2021-03-11 Anti- muc1-sea antibodies

Publications (2)

Publication Number Publication Date
JP2023517754A true JP2023517754A (ja) 2023-04-26
JPWO2021186427A5 JPWO2021186427A5 (enExample) 2024-03-18

Family

ID=75439163

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022555992A Pending JP2023517754A (ja) 2020-03-18 2021-03-11 抗ｍｕｃ１－ｓｅａ抗体

Country Status (20)

Country Link
US (1) US20230085269A1 (enExample)
EP (1) EP4087879A1 (enExample)
JP (1) JP2023517754A (enExample)
KR (1) KR20220161267A (enExample)
CN (1) CN115667312A (enExample)
AU (1) AU2021239078A1 (enExample)
BR (1) BR112022018629A2 (enExample)
CA (1) CA3171531A1 (enExample)
CL (1) CL2022002520A1 (enExample)
CO (1) CO2022014726A2 (enExample)
CR (1) CR20220523A (enExample)
CU (1) CU20220055A7 (enExample)
DO (1) DOP2022000193A (enExample)
EC (1) ECSP22080687A (enExample)
IL (1) IL296572A (enExample)
MX (1) MX2022011553A (enExample)
PE (1) PE20230602A1 (enExample)
PH (1) PH12022552445A1 (enExample)
WO (1) WO2021186427A1 (enExample)
ZA (1) ZA202211303B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR132043A1 (es) * 2023-03-03 2025-05-21 Beigene Switzerland Gmbh Anticuerpos muc1 y métodos de uso
CN120813609A (zh) * 2023-03-03 2025-10-17 广州百济神州生物制药有限公司 Muc1和cd16a抗体及使用方法
US20250041437A1 (en) 2023-07-31 2025-02-06 Sun Pharma Advanced Research Company Limited Humanized muc1 antibody and antibody drug conjugate

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008528623A (ja) * 2005-01-28 2008-07-31 ラモット アット テル アビブ ユニバーシティ， リミテッド 抗ＭＵＣ１のα／β抗体
WO2018174544A2 (ko) * 2017-03-21 2018-09-27 주식회사 펩트론 Muc1에 특이적으로 결합하는 항체 및 그의 용도
WO2019094626A1 (en) * 2017-11-08 2019-05-16 Fred Hutchinson Cancer Research Center Bispecific antibody compositions and related methods for improved pretargeted radioimunotherapies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
WO2010119704A1 (en) * 2009-04-17 2010-10-21 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
WO2015094106A1 (en) * 2013-12-19 2015-06-25 Arocell Ab Monoclonal anti-tk1 antibodies
KR102127421B1 (ko) * 2017-03-21 2020-06-26 주식회사 펩트론 Muc1에 특이적으로 결합하는 항체 및 그의 용도

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008528623A (ja) * 2005-01-28 2008-07-31 ラモット アット テル アビブ ユニバーシティ， リミテッド 抗ＭＵＣ１のα／β抗体
WO2018174544A2 (ko) * 2017-03-21 2018-09-27 주식회사 펩트론 Muc1에 특이적으로 결합하는 항체 및 그의 용도
WO2019094626A1 (en) * 2017-11-08 2019-05-16 Fred Hutchinson Cancer Research Center Bispecific antibody compositions and related methods for improved pretargeted radioimunotherapies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CANCER RESEARCH, vol. 72(13), JPN6025008604, 2012, pages 3324 - 3336, ISSN: 0005687880 *

Also Published As

Publication number Publication date
KR20220161267A (ko) 2022-12-06
CA3171531A1 (en) 2021-09-23
ECSP22080687A (es) 2022-12-30
US20230085269A1 (en) 2023-03-16
EP4087879A1 (en) 2022-11-16
CN115667312A (zh) 2023-01-31
PH12022552445A1 (en) 2023-11-20
DOP2022000193A (es) 2023-03-23
IL296572A (en) 2022-11-01
CU20220055A7 (es) 2023-06-13
BR112022018629A2 (pt) 2023-03-07
CL2022002520A1 (es) 2023-03-10
PE20230602A1 (es) 2023-04-10
CO2022014726A2 (es) 2023-02-16
AU2021239078A1 (en) 2022-08-11
MX2022011553A (es) 2023-01-04
ZA202211303B (en) 2025-08-27
CR20220523A (es) 2023-01-23
WO2021186427A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
US11033634B2 (en) Light chain variable regions
JP7562528B2 (ja) 抗体及びその用途
KR101782487B1 (ko) 신규 항-메소텔린 항체 및 이를 포함하는 조성물
JP2021120382A (ja) 部位特異的抗体コンジュゲーション方法および組成物
AU2018223053A1 (en) Novel modulators and methods of use
JP2005516965A (ja) 抗ｍｕｃ１８抗体を使用する方法
JP2019516705A (ja) 神経内分泌移行のリスクのある腫瘍を治療するための抗ｄｌｌ３薬物コンジュゲート
AU2021337687A1 (en) Nectin-4 antibodies and uses thereof
CN107001452A (zh) 用于治疗癌症的抗ck8抗体
JP2023517754A (ja) 抗ｍｕｃ１－ｓｅａ抗体
KR20090130335A (ko) 암 세포 세포독성을 매개하는 인간화 및 키메라 항-ｃｄ５９ 항체
EP4079758A1 (en) Semg2 antibody and use thereof
KR20230156021A (ko) Ror1 결합 단백질 및 이의 용도
EA049289B1 (ru) Антитела к sea-muc1
OA20958A (en) Anti- MUC1-sea antibodies
WO2018142323A1 (en) Anti-psma antibodies and uses thereof for diagnostic and therapeutic applications

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240307

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251211